Last updated: 16 March 2021 at 8:57am EST

Tyrell Rivers Net Worth



Tyrell Rivers biography

Dr. Tyrell J. Rivers Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has held this position since 2014. Prior to this role, Dr. Rivers was at MedImmune Ventures from 2009 until 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he worked in various technical and business roles of increasing responsibility. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Cerapedics, Inc., and Corvidia Therapeutics, Inc. and previously G1 Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Rivers holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business. Rivers is qualified to serve as a member of our board of directors based on his experience in the life sciences, biotechnology and pharmaceutical industries and his knowledge of corporate development matters.



How old is Tyrell Rivers?

Tyrell Rivers is 47, he's been the Independent Director of Viela Bio since 2018. There are 8 older and 3 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.

What's Tyrell Rivers's mailing address?

Tyrell's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.

Insiders trading at Viela Bio

Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong, and Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.



What does Viela Bio do?

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.



What does Viela Bio's logo look like?

Viela Bio, Inc. logo

Viela Bio executives and stock owners

Viela Bio executives and other stock owners filed with the SEC include: